DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



5HT3 Antagonism and Auditory Gating in Schizophrenia

Information source: Department of Veterans Affairs
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: ondansetron (Drug); neuropsychological testing (Behavioral); nicotine (Drug); haloperidol (Drug)

Phase: N/A

Status: Completed

Sponsored by: Department of Veterans Affairs

Summary

The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Clinical Details

Official title: 5HT3 Antagonism and Auditory Gating in Schizophrenia

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Subjects with diagnosed with schizophrenia will be studied.

Locations and Contacts

VAMC, Denver, Colorado 80013, United States
Additional Information

Starting date: June 1998
Ending date: June 2003
Last updated: June 23, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012